Cytokine alterations in psoriasis: an updated review

Seyedmirzaei, Homa; Rezaei, Nima

doi:10.1080/1744666x.2022.2011720

Cited by 8 publications

(6 citation statements)

References 147 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several scientific reports confirmed that psoriasis has an overexpression of pro-inflammatory type 1 cytokines, which is assumed to be pathophysiologically significant [2,5,6]. Based on knowledge from traditional Greco-Arab and Islamic herbal medicine, FS is highly recommended in the management of various skin diseases.…”

Section: Resultsmentioning

confidence: 99%

“…In this in vitro study, we evaluated the cytotoxicity, cytostatic, as well as antiinflammatory mechanism of water/ethanolic extracts of FS leaves and fruits by measuring the production of both anti-inflammatory (IL-10) and pro-inflammatory (NO, IL-6, and TNF-α) mediators in the human keratinocyte cell line HaCaT and human THP-1-derived macrophages and their co-cultures. We applied a co-culture system of HaCaT and THP-1-derived macrophages to mimic the in vivo situation where both cell types contribute to the manifestation of psoriasis [2,5,6].…”

Section: Resultsmentioning

confidence: 99%

“…Keratinocyte hyperproliferation in the basal and suprabasal epidermal regions, infiltration of hugely important inflammatory cells like macrophages, dendritic cells, neutrophils, lymphocytes, and T helper (TH) cells, and stressed keratinocytes that produce reactive oxygen and nitric oxide as well as proinflammatory cytokines and chemokine [5]. Production of the cytokines by THP-1-derived macrophages were examined in the culture supernatants using commercial ELISA kits.…”

Section: Suppression Of Pro-inflammatorymentioning

confidence: 99%

“…Following psoriasis therapy, these cytokine levels in the serum reduced. In contrast, psoriasis patients had lower blood levels of the anti-inflammatory cytokine IL-10, which had a negative correlation with PASI [5][6][7]. IL-10 has a significant impact on immunomodulation [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Modulatory Effects of Leave and Fruit Extracts of Ficus sycomorus on Cytostatic and Inflammatory Mediators in Monocultures and Co-cultures of Human Keratinocyte (HaCat) and Human Monocyte (THP-1) Cell Lines

Kmail

Mansour²,

Hanaisheh³

et al. 2022

EJMP

View full text Add to dashboard Cite

Background: Ficus sycomorus is one of the recommended antipsoriatic medicinal plants in the traditional Greco-Arab herbal medicine. However, the knowledge on its action mechanisms is limited. Aims: Cytotoxic, cytostatic, and anti-inflammatory effects of water/ethanolic extracts of Ficus sycomorus leaves and fruits were evaluated to test their role in the traditionally known antipsoriatic properties. Place and Duration of Study: All the experiments were done in the Department of Biology and Biotechnology, Arab American University-Palestine in 2020. Plants were collected from the Northern region of the West Bank/Palestine during the fall months in 2019 and given (Voucher code: Pharm-PCT-1030) at An-Najah National University. Methodology: MTT assay was used to evaluate cytostatic and cytotoxic effects of Ficus sycomorus extracts in human skin keratinocyte cell line (HaCaT), human monocytic cell line (THP-1)-derived macrophages, and their co-cultures. Commercial ELISA kits were applied to measure the cytokine levels. Results: Both extracts exhibited cytostatic effects with IC 50 of 656 μg/mL and 886 μg/mL for HaCat and co-culture, respectively. Leaves and fruits extracts significantly reduced dose-dependently the LPS-induced NO production by THP-1-derived macrophages from 65 μM to 19 μM and 16 μM, respectively. The fruit extracts showed higher effects than the leaf extracts and reduced the TNF-α levels from 709 pg/mL to 208 pg/mL. The fruit extracts increased the production levels of IL-10 from 74 pg/mL to 90 pg/mL. Conclusion: Ficus sycomorus extracts probably exert their antipsoriatic effects through cytostatic effects and modulation of the production levels of pro-inflammatory and anti-inflammatory cytokines.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Suppression Of Pro-inflammatorymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Modulatory Effects of Leave and Fruit Extracts of Ficus sycomorus on Cytostatic and Inflammatory Mediators in Monocultures and Co-cultures of Human Keratinocyte (HaCat) and Human Monocyte (THP-1) Cell Lines

Kmail

Mansour²,

Hanaisheh³

et al. 2022

EJMP

View full text Add to dashboard Cite

show abstract

“…Due to the chronic nature of psoriasis [1][2][3], the affected patients may experience several comorbidities (i.e., respiratory [4][5][6][7][8], cardiovascular [9][10][11][12][13] or gastrointestinal ones [14][15][16][17]) and therapy failures [18][19][20][21][22][23][24][25]. Thus, therapeutic strategies play a pivotal in limiting the psoriasis detrimental progression and the quality of life worsening.…”

Section: Introductionmentioning

confidence: 99%

Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching

et al. 2022

View full text Add to dashboard Cite

Since psoriasis (PsO) is a chronic inflammatory disease, patients may experience a drug failure also with very effective drugs (i.e., secukinumab) and, consequently, dermatologists have two therapeutic options: switching or perform a combination therapy (rescue therapy) to save the drug that had decreased its efficacy. At the moment no studies focused on combination/rescue therapy of secukinumab, so we performed a 52-weeks multicenter retrospective observational study that involved 40 subjects with plaque psoriasis that experienced a secondary failure and were treated with combination therapy (ciclosporin (n = 11), MTX (n = 15), NB-UVB (n = 7) and apremilast (n = 7)). After 16 weeks of rescue/combination therapy, PASI and a DLQI varied respectively from 8 [7.0–9.0] and 13 [12.0–15.0], to 3 [2.8–4.0] and 3 [2.0–3.3]), suggesting a significant improvement of daily functionality and quality of life. Results were maintained at 52 weeks. No side effects were experienced during the study. Secukinumab remains a safety and effective drug for PsO patients also in the IL-23 and JAK inhibitors era. The rescue therapy is a valid therapeutic option in case of secukinumab secondary failure.

show abstract